Hims & Hers Shares Rebound Following Regulatory Setback
Published on 09/20/2025 at 05:00 | Redaktion boerse-global.deThe stock of telehealth company Hims & Hers Health, Inc. experienced a period of significant volatility after receiving a formal warning from the U.S. Food and Drug Administration (FDA). Despite an initial sharp sell-off, the equity demonstrated notable resilience, staging a partial recovery that has left market participants divided on its near-term prospects.
Investor sentiment soured dramatically on September 16 when the FDA’s warning letter became public knowledge. The announcement triggered an immediate sell-off, sending shares down by as much as 8% during the trading session. The decline reflected mounting concerns over potential legal repercussions and lasting damage to the company’s brand reputation.
However, in a surprising reversal, the stock rallied on September 19. It climbed 3.5% at one point... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
